Pharmaceutical Anti-Counterfeiting: Combating the Real Danger from Fake Drugs

Front Cover
John Wiley & Sons, Aug 4, 2011 - Medical - 426 pages
This book overviews and integrates the business and technical issues that pharmaceutical companies need to know in order to combat the major global problem of counterfeit medicines. In addition to discussion of the problems, the author Davison addresses analytical techniques scientists use to detect counterfeits and presents some possible solutions to the threat of counterfeit medical products. Coverage moves from basic overview of the problem, costs / risks to consumers (toxic products, mistrust of drug companies) and business (revenue loss, public trust), government oversight and regulation, authentication strategies (packaging, analytical techniques), product tracking and supply chain, and case studies from around the globe.

From inside the book

 

Results 1-5 of 86

Page ix
... Issues 65 Legal Framework / 66 Link with Reimbursement and Social Healthcare / 68 Law Enforcement Issues / 69 Data Mining / 69 Money Transfer and Credit Cards / 70 Internet Service Providers and Search Engines / 71 9 Intellectual ...
Page xv
... Issues with 2D Codes / 237 Radio Frequency Identification (RFID) / 238 Mobile Phones / 242 Other Tracking Technologies / 244 Applicability of Tracking Systems Worldwide / 245 Data Format, Generation, and Storage 247 Serialization / 247 ...
Page xvii
... Issues 303 How to Work Together: Getting the Best from Security Partnerships / 303 What Do Pharmaceutical Companies Need? / 304 What Do Security Suppliers Need? / 305 What Do Print and Packaging Suppliers Need? / 306 General ...
Page xviii
... Issues / 324 Legal Approaches / 324 Conclusions / 325 Selected Examples from Around the World 329 Argentina / 329 Brazil / 330 Canada / 330 China / 330 European Union / 331 India / 331 Laos and Southeast Asia / 331 Nigeria / 331 Russia ...
Page xix
... INFORMATION SOURCES 379 General Readership / 379 Specialist Readership / 380 News / 381 Education / 381 Organizations / 381 DRUG REGULATORS 385 INDEX 391 Counterfeit drugs are fundamentally a security issue. Writing a book xix CONTENTS.

Where's the rest of this book?

Selected pages

Contents

Introduction
3
4
21
Risks and Costs for Governments
31
Protecting and Educating Consumers
49
Business Risks and Strategy
57
Government Issues
65
Intellectual Property and AntiCounterfeiting
73
Traceability or Authentication?
81
Adhesive
200
28
225
Geographical Perspectives
269
The Concept of Medicrime
275
EFPIA Pilot Coding Project
285
Product Tracking in Other Industries
291
Implementing AntiCounterfeiting InitiativesPractical
303
Where Do We Go from Here?
313

What Is Authentication?
87
Authentication of the Person
93
OnDose and InDose Authentication
103
Analytical Detection of Counterfeit Dosage Forms
113
Security Labels
145
Holograms and DOVIDs
153
Specialty Inks
159
New Models New Approaches
321
A PATIENTS GUIDE TO AVOIDING COUNTERFEIT DRUGS
337
GLOSSARY
363
INFORMATION SOURCES
379
173
398
Copyright

Other editions - View all

Pharmaceutical Anti-Counterfeiting: Combating the Real Danger from Fake Drugs
Mark Davison
Limited preview - 2011

Common terms and phrases

accessed active additional allow anti-counterfeiting application approach associated authentication become brand CHAPTER Combating common companies complex consumer contain cost counterfeit drugs countries crime criminal Danger detail device difficult discussed distribution dosage effective ensure European example fake drugs genuine global Health identify implementation important increase individual industry inks integrated involved issues John Wiley June label look manufacturer Mark materials means measures medicines methods necessary operations organizations original owner pack packaging patient pedigree pharmaceutical pharmacy placed possible potential practical prescription prevent printing problem product security protection Real record relatively removed require RFID risk seal security features serialization specific standard suppliers supply chain techniques trace tracking types unique unit usually Wiley & Sons

About the author (2011)

MARK DAVISON, CEO of Blue Sphere Health, is a pharmaceutical consultant and entrepreneur with more than twenty years of industry experience. He was formerly business development director for healthcare at SICPA, one of the world's leading anti-counterfeiting and product security technology providers, where he gained an in- depth, global perspective on counterfeit pharmaceuticals and medical devices. He is a writer, seminar leader, and international conference speaker on pharmaceutical security matters. His article "Drugs for the Developing World: Obligation, Opportunity and Threat" won the Royal Society of Medicine Oswald Morton Essay Prize in 2010.

Bibliographic information

TitlePharmaceutical Anti-Counterfeiting: Combating the Real Danger from Fake Drugs
AuthorMark Davison
Editionillustrated
PublisherJohn Wiley & Sons, 2011
ISBN1118023668, 9781118023662
Length426 pages
Subjects ›  › 

Medical / Pharmacology
Science / Chemistry / General
  
Export CitationBiBTeX EndNote RefMan